Aro Biotherapeutics’ Post

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update #finance #financial #finanzas #finanza

Read this article and comment below on what your thoughts were on it! Reach out if I can assist with anything! Please note our firm will not be intaking deals from other investment bankers, capital advisory firms, or capital brokers where the third party earns a fee on the funding. #rainstarcapital

Have the equivalent of over 100 analysts at your fingertips. Assess companies in minutes using our Cash Flow Returns On Investments based valuation and modeling tools. https://lnkd.in/eJXnSDxy

My latest article is out (and open access)! In this analysis of #financialization in US #biopharma, I show how "Our options for saving lives have been overdetermined by finance capitalism." https://lnkd.in/gqacEVN5

Our #MarketUpdate report for the week ending February 16th is now available. Highlights include:    🔉US equities ended the week with minor losses due to January’s CPI being higher than expected at 3.1% YoY and 0.3% MoM     🔉Despite the momentum that biotech IPOs have seen so far this year, last week saw no listings; however, 25 companies in the queue suggests that IPO activity will most likely remain elevated in the first half of the year     🔉Gilead Sciences made headlines by expanding their liver portfolio with their $4.3B acquisition of CymaBay Therapeutics, providing Gilead Sciences with CymaBay Therapeutics’s investigational lead candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) with FDA priority review and anticipated U.S. approval in the third quarter of 2024     🔉Freenome, developing blood tests for early cancer detection, raised a $254M venture round led by Roche and joined by a16z Life Sciences Growth Fund, Bain Capital Life Sciences Fund LP, RA Capital Management, and other flagship life sciences investors, making this deal the largest venture financing year-to-date    Read the full report here: https://bit.ly/42JY8k2     #Healthcare #MarketTrends #Biotech #IPO #Cancer #Theraputics #Lifesciences #BBLSA  

#PortfolioValue of Biopharma companies is under pressure from price regulation. What impact does the US #InflationReductionAct have on asset values? Read our perspective!

One of the most common questions we've heard over the last year is how the IRA will impact portfolio value. In this article, Rachel Fong, Tonny Huang, and I break down the provisions that will have the biggest impact, both good and bad. Check out the article below to learn more: https://lnkd.in/g7bby9wg

#InvestorNews: #EYPT to report Q4 2023 financial results and recent corporate developments at our upcoming webcast. Learn more below:

The Inflation Reduction Act is having profound effect on the US economy including in the biopharma sector. My colleagues Betty Pio, Tonny Huang and Rachel Fong explore how we should think about valuing pharmaceutical assets in the context of new economic models. #kearney #pharmaceutical #lifesciencesindustry

Lirentelimab out on failed phase II data; Allakos restructures